[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,236
Citations 0
From the JAMA Network
June 16, 2015

A Revised Quality Measure for Surgical CareMore Alpha Testing for Perioperative β-Blockers?

Author Affiliations
  • 1Department of Surgery, University of Toronto, Toronto, Ontario, Canada
  • 2Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
  • 3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
  • 4Division of Support, Systems, and Outcomes, Toronto General Research Institute, Toronto, Ontario, Canada
  • 5Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 6Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
JAMA. 2015;313(23):2369-2370. doi:10.1001/jama.2015.0798

Myocardial infarction is an important cause of disability and death after surgery, prompting interest in interventions to reduce the incidence of perioperative cardiovascular events. Since the 1980s, perioperative β-adrenergic blockers have been examined as a strategy to reduce the risk of perioperative myocardial ischemia in patients undergoing noncardiac surgery. β-Blockers may prevent the rupture of coronary plaques due to the physiologic stress of surgery1 and can reduce myocardial oxygen demand associated with catecholamine excess in the postoperative period.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×